• Explore /
  • Poster
  • / Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial.

Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial.

Abstract Poster

Authors

Antonio D'Alessio

Antonio D'Alessio

Humanitas University, Pieve Emanuele, Milan, Italy

Antonio D'Alessio , Madhava Pai , Duncan Spalding , Poyyamozhi Rajagopal , Thomas Talbot , Robert Goldin , Claudia A.M. Fulgenzi , Caroline Ward , Vincent Yip , Sarah Slater , Mikael Sodergren , Paul Tait , Nagy A. Habib , Robert Thomas , Alessio Cortellini , Rohini Sharma , David J. James Pinato

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03682276

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4093)

DOI

10.1200/JCO.2022.40.16_suppl.4093

Abstract #

4093

Poster Bd #

80

Abstract Disclosures

Similar Posters

First Author: Antonio D'Alessio

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Efficacy of nivolumab and ipilimumab in patients with hepatocellular carcinoma with prior immune-checkpoint inhibitor treatment.

Efficacy of nivolumab and ipilimumab in patients with hepatocellular carcinoma with prior immune-checkpoint inhibitor treatment.

First Author: Jaekyung Cheon

First Author: Yara L. Verschoor

First Author: Ahmed Omar Kaseb